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Plasma insulin-like growth factor in primary breast
cancer patients treated with adjuvant chemotherapy
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Summary Insulin-like growth factor 1 (IGF-1) plasma level was assayed in 60 breast cancer patients undergoing six courses of adjuvant
chemotherapy. The only observed variation was a slight decrease (10%) in IGF-1 concentrations, assayed before treatment, between the first
and the second courses of chemotherapy. During chemotherapy courses, there were no statistically significant variations in IGF-1. These
results suggest that chemotherapy, unlike the specific hormonal treatments tamoxifen and somatostatin, certainly does not act via a decrease
in plasma IGF-1.
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Insulin-like growth factor 1 (IGF-1) is a growth factor whose
major function is to mediate the effect of growth hormone on
skeletal growth. The major determinant of IGF-1 plasma concen-
tration is growth hormone (Zapf and Froesch, 1986). But many
other physiological parameters regulate human IGF-1 plasma
concentrations. These include age, sex, body composition, nutri-
tional status and some other additional minor variables: thyroxine,
prolactin, placental lactogen, oestrogen and androgen (Zapf and
Froesch, 1986; Thissen et al, 1994).
IGF-1 also acts as a local (autocrine or paracrine) factor, and it
is a potent mitogen for a number of normal and transformed cell
lines. IGF-1 stimulates the growth of various breast cancer cell
lines (Lee and Yee, 1995). IGF-l mRNAs do not seem to be
present in human breast cancer cells but are expressed in the breast
tumours, suggesting a paracrine role for this factor (Yee et al,
1989; Lee and Yee, 1995). Conversely, breast cancer cell lines
have been shown to produce binding proteins that modulate IGF-1
action; these cells and most breast cancer biopsies contain IGF-1
receptor (IGF-1-R) (Peyrat and Bonneterre, 1992). We have also
demonstrated a plasma IGF-1 increase in breast cancer patients
compared with a control population (Peyrat et al, 1993).
These results suggest that patients could benefit from a lowering
of IGF-1 plasma levels. Somatostatin analogues are able to
decrease IGF-1 plasma concentrations in breast cancer patients
(Manni et al, 1989; Pollack et al, 1989; Vennin et al, 1989). A
number of studies also suggest that one mode of action of
hormonotherapy could be a decrease in circulating IGF-1 (Colleti
et al, 1989; Pollack et al, 1989; Lonning et al, 1992; Reed et al,
1992; Friedl et al, 1993). The modulation of IGF-1-R signalling
pathway by tamoxifen has been demonstrated in human breast
cancer cells (Guvakova and Surmacz, 1997). Finally, in vitro
interactions between IGF-I and chemotherapy have been
demonstrated: IGF- 1 protects human breast cancer cell lines from
anti-cancer drug-induced cell death by reducing either necrosis
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(Geier et al, 1995) or apoptosis (Dunn et al, 1997). The present
work was undertaken to determine if chemotherapy is capable of
modulating IGF-1 plasma concentrations in patients with primary
breast cancer.
MATERIALS AND METHODS
Patients
Sixty patients were included in this study. They received six cycles
of adjuvant chemotherapy after surgery for locoregional breast
cancer. The chemotherapy was either FEC [epirubicin (50 or
100 mg m-2), fluorouracil and cyclophosphamide at the same dose
(500 mg m-2)] or MCF [fluorouracil (750 mg) intravenously from
day 1 to day 5, cyclophosphamide (500 mg) on days 1, 3 and 5 and
methotrexate (20 mg) on days 2 and 4].
For all the patients, blood samples were collected at 09.00 h on
the day before surgery in tubes with EDTA (through an indwelling
forearm catheter). Blood was then collected before each course of
treatment. In the patients receiving 5-day courses of chemo-
therapy, blood was also collected before treatment on day 5. The
plasma was separated by centrifugation, frozen and stored at
-20°C until assayed.
IGF1 assay
We described the IGF-I plasma radioimmunoassay in detail in a
previous paper (Peyrat et al, 1993). The antiserum (UBK 487)
used for the radioimmunoassay was a gift from Drs L Underwood
and J Van Wyk; it was distributed by the Hormone Distribution
Program of the National Institute for Diabetes, Digestive and
Kidney Diseases (NIDDK-USA) through the National Hormone
and Pituitary Program. As specified by the NIDDK, the antiserum
was used in a final dilution of 1:18 000 and has 0.5% cross-
reactivity with IFG-2 cross-reacting minimally with insulin at 10-6
M. The IGF-1 for standards was purchased from Amersham (ARN
4010; Amersham, France); 1 ng of this recombinant DNA-derived
ThR-59 analogue of IGF-I (produced by AMGEN) is equivalent
to 0.0067 units. This product was labelled with'I21 using a low
chloramine T concentration method (RAS 200 ltCi ,ug-'). The
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serum was acid-ethanol extracted to avoid interferences from IGF-
binding proteins. Standards and unknowns were then incubated for
1 h at 4°C with the antibody before the addition oflabelled IGF-1;
an overnight incubation with ['251]IGF-l was achieved, and the
antibody-bound ['251]IGF-1 was precipitated using goat anti-rabbit
gamma-globulin as carrier. The sensitivity of the assay was
10 ng ml-l (B/BO = 90%). The intra-assay variation coefficient was
6%; the inter-assay variation coefficient was 12%.
Statistical methods
As the distribution ofIGF-I plasmaconcentration values could not
be established as normal, non-parametric tests were used. The
localization of the population values was indicated by median
value, the dispersion by lowest and highest values. Differences
between populations were tested using the Wilcoxon test for
paired values. Graphic representations of the studied populations
were performed using the box plot visual method.
RESULTS
The median IGF-1 plasma concentrations at the beginning ofeach
of the six courses of adjuvant chemotherapy in 60 patients are
represented in Figure 1. The IGF-1 median level was significantly
higher at the beginning ofthe first chemotherapy course than at the
beginning ofthe following courses (P < 0.01).
The median level of IGF-I at the beginning of each 5-day
course of chemotherapy was not different from the IGF-1 median
level at the end of each 5-day course; however, this study was
performed on only 67 total pairs (data not shown).
The median age of these patients was 51 years. The median
level ofIGF-1 at the time ofthe operation was 142 ng ml-, signif-
icantly higher than the median level at the beginning of each
course of chemotherapy (P < 0.01). The median time between
surgery and chemotherapy was 1 month (in 12 patients, 15 days; in
35 patients, 1 month; in seven patients, 2 months; and in six
patients, 3 months or more).
DISCUSSION
Our results show a 10.6% (142 to 127) IGF-1 decrease in median
levels of IGF-1 between the surgery and the first adjuvant
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Figure 1 IGE-1 plasma concentrations at the beginning of each course of
adjuvant chemotherapy in breast cancer patients
chemotherapy course and another 10% (127 to 114) decrease
between the first and the second course. Then, from the second
course to the last one, there was no variation in the IGF-1 plasma
concentrations obtained at the beginning of each course. These
results were confirmed in subgroups which took into account the
type ofchemotherapy (data not shown).
The 10% decrease during adjuvant chemotherapy was lower
than the 30-50% decrease described during adjuvant tamoxifen
treatment (Colleti et al, 1989; Pollack et al, 1989; Lonning et al,
1992; Reed et al, 1992; Friedl et al, 1993). It was also much lower
than the 30-70% IGF-I decrease observed during somatostatin
treatment of advanced breast cancer patients (Manni et al, 1989;
Pollack et al, 1989; Vennin et al, 1989).
In a previous study (Peyrat et al, 1993) with a different popula-
tion of breast cancer patients, we demonstrated that the median
concentration of IGF-1 was significantly higher in patients with
primary breast cancer (median level = 152 ng ml-') than in the
control population (median level = 115 ng ml-'). In the present
population, the median IGF-1 concentration in serum obtained
before surgery was 142 ng ml-', and this was very close to the
median IGF-1 levels obtained in the previously studied primary
breast cancer population. The origin of the high IGF-l concentra-
tion in breast cancer is difficult to specify. In the present study, we
observed an IGF-1 decrease between the surgery and the second
course ofchemotherapy that occurs 2 months later. The hypothesis
is that high IGF-1 plasma concentrations in primary breast cancer
could result directly from the production of IGF-1 or insulin-like
growth factor-binding proteins by the tumour tissue. It should be
noted that, inpapers dealing with the decrease in IGF-1 induced by
tamoxifen, the time between surgery and treatment is not specified
(Colleti et al, 1989; Pollack et al, 1989; Lonning et al, 1992; Reed
et al, 1992; Friedl et al, 1993), and it is possible to imagine that, to
some extent, the decrease in IGF-1 that occurs early in treatment is
due to the removal ofthe tumour.
Finally, in patients receiving a 5-day protocol, the IGF-1 plasma
level measured on the fifth day was not different from the level
measured on the first day ofthe course, demonstrating the absence
ofeffect ofchemotherapy on IGF-1 levels.
In conclusion, these results suggest that chemotherapy, unlike
the specific hormonal treatments, tamoxifen and somatostatin, is
unable to decrease plasma IGF-1 concentrations in breast cancer
patients.
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